Mozaffar Aznab

Prof. Mozaffar Aznab


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MAMozaffar Aznab
Mozaffar Aznab

27 August 2015 in Hematological Oncology
Verified
Journal Article
Open access
PDF file
MAMozaffar Aznab
Mozaffar Aznab
MRMansour Rezaei
Mansour Rezaei
The aim of this study was to evaluate the effect of arsenic trioxide as a single agent in acute promyelocytic leukaemia cases for induction, consolidation, and maintenance therapy in a long-term, 11-year follow-up. We studied 60 patients with acute promyelocytic leukaemia. Sixty percent of the patients were aged between 12 and 24 years. Arsenic trioxide was infused at a 0.15 mg/kg daily dose until complete remission was achieved. After 2 weeks of rest, arsenic trioxide was infused daily for 28 days as a consolidation therapy. Then, arsenic infusions were given every 3–4 months for 14 days for 2 years, and the patients were followed until relapse or death. The rates of complete remission, disease-free survival, overall survival, and drug toxicity were evaluated. The morphologic complete remission was observed in 55 out of the 60 patients. The most common causes of a remission failure were early mortality because of the APL differentiation syndrome and the lack of response to arsenic treatment. The mean follow-up was 90 months. The primary outcomes for males and females were a mean disease-free survival of 101 and 97 months, respectively, and a mean overall survival of 103 and 101 months, respectively. From the 55 cases with remission, three patients died (late mortality). Of the 60 patients, 85% are still alive. Arsenic trioxide was generally well tolerated. The long-term follow-up of patients with APL, treated with arsenic alone as induction, consolidation, and maintenance therapy, shows high cure rates and excellent outcomes. Copyright © 2015 John Wiley & Sons, Ltd.

1 July 2019 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
MAMozaffar Aznab
Mozaffar Aznab
DMDavood Maleksabet
Davood Maleksabet
SKSdigheh Khazaei
Sdigheh Khazaei
MKMansour Khazaei
Mansour Khazaei
MRMansour Rezaei
Mansour Rezaei
Objective: Gastric cancer is one of the oncological challenges, and tendency toward target therapy in this cancerhas been increased. Controversy still exists on prognostic value of HER2/neu expression and its relationship withclinicopathological characteristics and survival of gastric cancer patients. In this regard, the present study examinedthe status of HER2/neu in patients with gastric cancer and its prognostic effects. Methods: Pathological samples of 97gastric cancer patients diagnosed over the last 8 or 9 years (from 2008 to the end of 2017) and treated with 5-fluorouracil,Docetaxel, and Cisplatin (TCF) were studied in this investigation. Patients were assigned to two groups according totheir HER2/neu status. First group included patients with positive HER2/neu (Score 3) and second group involvedpatients with negative HER2/neu (Score 0 and 1). Patients were compared in terms of disease stage, survival rate,and mortality. Results: The mean age of patients was 58 years old. There were 75 men and 22 women in this study.In terms of disease stage, 4, 21, 41, and 31 patients were in stage I, II, III, and IV, respectively. Using IHC method,it was found that 27, 23, 25, and 22 patients had HER2/neu expression with score 0, score +1, score 2+ and score+3,respectively. We discovered that expression of positive HER2/neu was associated with male sex. We also observedthat survival and mortality rates following treatment initiation were significantly different between HER2/neu positiveand negative gastric cancer patients (P<0.01). Conclusion: Evaluation of HER2/neu status in gastric cancer patientsshowed that HER2/neu 3+ expression could reduce the patients’ survival. Therefore, it is recommended that patientswho may benefit from trastuzumab, be treated. A clinical multi-center trial should be also considered for use of thisdrug in adjuvant cases.

19 February 2019 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
YMYosra Maleki
Yosra Maleki
ZAZahra Alahbakhshi
Zahra Alahbakhshi
ZHZahra Heidari
Zahra Heidari
MMMohammad-Taher Moradi
Mohammad-Taher Moradi
ZRZiba Rahimi
Ziba Rahimi
FBFariborz Bahremand
Fariborz Bahremand
Mutations in certain genes have been suggested to be associated with the pathogenesis of chronic lymphocytic leukemia (CLL), which is the most common leukemia in adults. In a case‑control study, 100 patients with CLL and 105 healthy individuals were investigated for Notch homolog 1, translocation‑associated (Drosophila) (NOTCH1) c.7544‑7545delCT, recombinant splicing factor 3B subunit 1 (SF3B1) c.2098A>G, mouse double minute 2 homolog (MDM2) 40‑bp insertion/deletion and myeloid differentiation primary response 88 (MYD88) L265P mutations by using allele specific‑polymerase chain reaction (AS‑PCR), a designed AS‑PCR, PCR and PCR‑restriction fragment length polymorphism methods, respectively. The presence of NOTCH1 and SF3B1 mutations were confirmed by genomic DNA sequencing. The NOTCH1 mutation was detected in 10% of patients and not detected in the control group. A higher frequency of NOTCH1 mutation was detected in patients with stage III CLL (62.5%) compared with stages 0‑II CLL (37.5%) (odds ratio, 4.69‑fold; 95% confidence interval, 1.0‑21.9; P=0.049). The SF3B1 mutation was observed in 12% of the patients compared with 1.9% of the controls (P=0.012). The presence of MDM2 polymorphism was not associated with the risk or the stage of the disease. In addition, the MYD88 L265P mutation was not detected in the patients or the controls. The current study established the frequency of NOTCH1, SF3B1, MDM2 and MYD88 mutations in patients with CLL from the Kurdish population of Western Iran. In summary, a high frequency of NOTCH1 and SF3B1 mutations were identified in patients with CLL compared with healthy individuals, and the NOTCH1 mutation was associated with a high stage of the disease.

20 September 2020 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
Amin JalilvandAmin Jalilvand
Amin Jalilvand
KYKheirollah Yari
Kheirollah Yari
MAMozaffar Aznab
Mozaffar Aznab
ZRZohreh Rahimi
Zohreh Rahimi
IFIman Salahshouri Far
Iman Salahshouri Far
PMPantea Mohammadi
Pantea Mohammadi
Objective: The current research was conducted to study the association between the SNP309 and del1518 polymorphisms with the breast cancer in the patients with the Kurdish ethnic background from western Iran. Also, a systematic review of the relevant case‐control studies on theMDM2polymorphisms in the patients with breast cancer was performed.Methodology: Two mL of peripheral blood was taken from 100 patients with breast cancer and 100 healthy individuals. The frequencies ofMDM2SNP309 and del1518 genotypes and alleles were determined using the PCR‐RFLP and PCR methods, respectively.Results: The frequency of the TT, TG, and GG ofMDM2‐SNP309 genotypes in the patients was obtained as 23%, 52%, and 25%, and they were equal to 22%, 40%, and 38% in the control group, respectively. Also, considering theMDM2‐del1518 polymorphism, the frequencies of ins/ins, ins/del, and del/del genotypes were equal to 52%, 41%, and 7% in the breast cancer group and they were equal to 62, 30, and 8% in the control group, respectively. Analysis of the results indicated that the GG genotype plays a protective role for the breast cancer in the recessive model (GG vs TT + TG) of SNP309 (χ2 = 3.916,P = .048, and OR = 0.54).Conclusion: Our findings revealed that the GG genotype ofMDM2‐SNP309 can play a protective role in the breast cancer disease. Also, our systematic review indicated that the SNP309, SNP285, and del1518 ofMDM2gene in different populations mostly did not have a significant association with the risk of breast cancer.

22 October 2018 in International Journal of Hematology-Oncology and Stem Cell Research
Verified
Journal Article
Open access
MAMozaffar Aznab
Mozaffar Aznab
ANAnisodowleh Nankali
Anisodowleh Nankali
SDSara Daeichin
Sara Daeichin
Background: The present study was conducted to determine the response to treatment in patients with GTN, the survival rate and to investigate the outcomes of first pregnancy after chemotherapy. Materials and Methods: The treatment protocol was based on the FIGO Staging of GTN and the Modified WHO Prognostic Scoring. Results: Complete remission was achieved with MTX in 100% of the low-risk patients and with combination therapy in 91% of the high-risk cases. Out of 27 low-risk patients, 21 had no metastasis 6 had lung metastasis, 18 preserved their fertility and conceived in the first year following the chemotherapy. Out of 3 patients who had developed invasive moles, 1 got pregnant after chemotherapy. Four of the patients with choriocarcinoma conceived in the first year following the chemotherapy. In the patient with placental site trophoblastic tumors, there was no pregnancy due to hysterectomy. Conclusion: GTN was found to be a chemosensitive condition, but more effective therapeutic protocols are therefore required. Keywords: Gestational trophoblastic neoplasia, Choriocarcinoma, High dose chemotherapy, Pregnancy